期刊
MOLECULAR CANCER RESEARCH
卷 19, 期 2, 页码 207-214出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1541-7786.MCR-20-0708
关键词
-
资金
- NIH-NCI [R01 CA212600]
- Diversity Supplemental Award [3R01CA212600-03S1]
- W. Kim Foster Pancreatic Cancer Research Fund
- NCI of the NIH under Cancer Center Support grant [5P30CA056036-17, R00 CA178177 NIH]
- Pancreatic Cancer Action Network-AACR Research Acceleration Network Grant [15-90-25-BROD]
- NCI, NIH [U01CA224012]
The DDR pathway is crucial for tumorigenesis, and therapeutic approaches targeting DDR include enhancing the efficacy of cytotoxic chemotherapies and increasing DNA damage through synergistic drug strategies. Coinhibition of PARG and Wee1 was found to synergistically decrease cell survival and increase DNA damage in an S-phase-dependent manner.
The DNA damage response (DDR) pathway sets the stage for tumorigenesis and provides both an opportunity for drug efficacy and resistance. Therapeutic approaches to target the DDR pathway include aiming to increase the efficacy of cytotoxic chemotherapies and synergistic drug strategies to enhance DNA damage, and hence cell death. Here, we report the first preclinical evaluation of a novel synergistic approach by using both genetic and small-molecule inhibition methods of silencing the DDR-related protein, poly (ADP-ribose) glycohydrolase (PARG), and the checkpoint kinase inhibitor, Wee1, in pancreatic ductal adenocarcinoma (PDAC) and colorectal carcinoma cells in vitro and in vivo. Mechanistically, we demonstrate that coinhibition of PARG and Wee1 synergistically decreased cell survival and increased DNA damage in an S-phase-dependent manner.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据